First-Line Treatment of Anal Squamous Cell Carcinoma with Extrapelvic Metastatic Disease
When anal squamous cell carcinoma has spread beyond the pelvis, the clinical approach shifts to systemic management. Identifying the appropriate first-line regimen — and knowing how to adjust it based on tolerability — is central to decision-making in this setting.
Clinical Scenario
Anal squamous cell carcinoma with confirmed extrapelvic metastatic disease. Systemic therapy is generally recommended for patients in this situation.
First-Line Approach
Management is based on combination systemic chemotherapy. A preferred platinum-based doublet — supported by data from a phase II international multicentre study — is identified, alongside several alternative combination regimens that vary in their toxicity profiles. Guidance on managing cumulative toxicity and agent continuation is also part of the protocol.
Full regimen selection criteria, alternative options, and toxicity-based modification rules are in the complete protocol →
References
DOI: 10.6004/jnccn.2023.0030
- Systemic therapy is generally recommended for extrapelvic metastatic disease.
- Based on results from the phase II International Multicentre InterAACT study, carboplatin in combination with paclitaxel has been noted as the preferred regimen for first-line treatment of metastatic anal cancer by the NCCN Panel.
- Other recommended treatment options include 5-FU, leucovorin, and cisplatin (FOLFCIS); 5-FU, leucovorin, and oxaliplatin (FOLFOX); 5-FU + cisplatin (category 2B reflecting its similar efficacy, but higher toxicity, when compared with carboplatin + paclitaxel in a randomized trial); or modified docetaxel, cisplatin, and 5-FU (DCF, category 2B).
- With use of FOLFOX, the panel recommends strong consideration of discontinuation of oxaliplatin after 3-4 months (or sooner for unacceptable neurotoxicity) while maintaining other agents until time of disease progression.
View source ↗